Literature DB >> 20811474

Low bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138(+) cells.

S Colla, P Storti, G Donofrio, K Todoerti, M Bolzoni, M Lazzaretti, M Abeltino, L Ippolito, A Neri, D Ribatti, V Rizzoli, E Martella, N Giuliani.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20811474     DOI： 10.1038/leu.2010.193

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  46 in total

1.  Myeloma as a model for the process of metastasis: implications for therapy.

Authors:  Irene M Ghobrial
Journal:  Blood       Date:  2012-04-24       Impact factor: 22.113

2.  Adaptation to survival in germinal center is the initial step in onset of indolent stage of multiple myeloma.

Authors:  Ariosto S Silva; Robert A Gatenby
Journal:  Mol Pharm       Date:  2011-10-12       Impact factor: 4.939

3.  The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells.

Authors:  Paola Storti; Denise Toscani; Irma Airoldi; Valentina Marchica; Sophie Maiga; Marina Bolzoni; Elena Fiorini; Nicoletta Campanini; Eugenia Martella; Cristina Mancini; Daniela Guasco; Valentina Ferri; Gaetano Donofrio; Franco Aversa; Martine Amiot; Nicola Giuliani
Journal:  Haematologica       Date:  2015-12-11       Impact factor: 9.941

Review 4.  The bone-marrow niche in MDS and MGUS: implications for AML and MM.

Authors:  Irene M Ghobrial; Alexandre Detappe; Kenneth C Anderson; David P Steensma
Journal:  Nat Rev Clin Oncol       Date:  2018-01-09       Impact factor: 66.675

Review 5.  Pathogenesis beyond the cancer clone(s) in multiple myeloma.

Authors:  Giada Bianchi; Nikhil C Munshi
Journal:  Blood       Date:  2015-04-02       Impact factor: 22.113

6.  Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma.

Authors:  Naoya Mimura; Mariateresa Fulciniti; Gullu Gorgun; Yu-Tzu Tai; Diana Cirstea; Loredana Santo; Yiguo Hu; Claire Fabre; Jiro Minami; Hiroto Ohguchi; Tanyel Kiziltepe; Hiroshi Ikeda; Yutaka Kawano; Maureen French; Martina Blumenthal; Victor Tam; Nathalie L Kertesz; Uriel M Malyankar; Mark Hokenson; Tuan Pham; Qingping Zeng; John B Patterson; Paul G Richardson; Nikhil C Munshi; Kenneth C Anderson
Journal:  Blood       Date:  2012-04-26       Impact factor: 22.113

7.  Promising therapies in multiple myeloma.

Authors:  Giada Bianchi; Paul G Richardson; Kenneth C Anderson
Journal:  Blood       Date:  2015-06-01       Impact factor: 22.113

8.  Angiogenesis and multiple myeloma.

Authors:  Nicola Giuliani; Paola Storti; Marina Bolzoni; Benedetta Dalla Palma; Sabrina Bonomini
Journal:  Cancer Microenviron       Date:  2011-07-07

Review 9.  Integration of hypoxic HIF-α signaling in blood cancers.

Authors:  L Schito; S Rey; M Konopleva
Journal:  Oncogene       Date:  2017-05-22       Impact factor: 9.867

10.  Hypoxia promotes IL-32 expression in myeloma cells, and high expression is associated with poor survival and bone loss.

Authors:  Muhammad Zahoor; Marita Westhrin; Kristin Roseth Aass; Siv Helen Moen; Kristine Misund; Katarzyna Maria Psonka-Antonczyk; Mariaserena Giliberto; Glenn Buene; Anders Sundan; Anders Waage; Anne-Marit Sponaas; Therese Standal
Journal:  Blood Adv       Date:  2017-12-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.